VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISHL12 2022 | Current and future perspectives for prognostication and MRD in Hodgkin lymphoma

Sven Borchmann, MD, University of Cologne, Cologne, Germany, shares some insights into the importance of improving tools used for the prognosis and diagnosis of patients with Hodgkin lymphoma (HL). Dr Borchmann first highlights challenges in the treatment of patients with HL, and then goes on to explain the importance of individualizing treatment and using biological factors and measurable residual disease (MRD) to improve prognostication. This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Ownership interest in and founder of Liqomics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter